JP2014505045A5 - - Google Patents

Download PDF

Info

Publication number
JP2014505045A5
JP2014505045A5 JP2013546193A JP2013546193A JP2014505045A5 JP 2014505045 A5 JP2014505045 A5 JP 2014505045A5 JP 2013546193 A JP2013546193 A JP 2013546193A JP 2013546193 A JP2013546193 A JP 2013546193A JP 2014505045 A5 JP2014505045 A5 JP 2014505045A5
Authority
JP
Japan
Prior art keywords
compound
item
composition
composition according
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013546193A
Other languages
English (en)
Japanese (ja)
Other versions
JP5891241B2 (ja
JP2014505045A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/064017 external-priority patent/WO2012087596A1/en
Publication of JP2014505045A publication Critical patent/JP2014505045A/ja
Publication of JP2014505045A5 publication Critical patent/JP2014505045A5/ja
Application granted granted Critical
Publication of JP5891241B2 publication Critical patent/JP5891241B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013546193A 2010-12-20 2011-12-08 Hcvを処置するための組合せ Active JP5891241B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201061425194P 2010-12-20 2010-12-20
US61/425,194 2010-12-20
US201161495841P 2011-06-10 2011-06-10
US61/495,841 2011-06-10
PCT/US2011/064017 WO2012087596A1 (en) 2010-12-20 2011-12-08 Combinations for treating hcv

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015243341A Division JP6162206B2 (ja) 2010-12-20 2015-12-14 Hcvを処置するための組合せ

Publications (3)

Publication Number Publication Date
JP2014505045A JP2014505045A (ja) 2014-02-27
JP2014505045A5 true JP2014505045A5 (enExample) 2015-01-29
JP5891241B2 JP5891241B2 (ja) 2016-03-22

Family

ID=45446195

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013546193A Active JP5891241B2 (ja) 2010-12-20 2011-12-08 Hcvを処置するための組合せ
JP2015243341A Active JP6162206B2 (ja) 2010-12-20 2015-12-14 Hcvを処置するための組合せ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015243341A Active JP6162206B2 (ja) 2010-12-20 2015-12-14 Hcvを処置するための組合せ

Country Status (10)

Country Link
US (3) US20130273005A1 (enExample)
EP (1) EP2654900A1 (enExample)
JP (2) JP5891241B2 (enExample)
AR (1) AR084237A1 (enExample)
AU (1) AU2011349844B2 (enExample)
CA (1) CA2822037A1 (enExample)
NZ (1) NZ613370A (enExample)
TW (2) TW201306841A (enExample)
UY (1) UY33797A (enExample)
WO (1) WO2012087596A1 (enExample)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
PL359169A1 (en) 2000-05-26 2004-08-23 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses
AU2003298658A1 (en) 2002-11-15 2004-06-15 Idenix (Cayman) Limited 2'-branched nucleosides and flaviviridae mutation
UY32306A (es) 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
SG176015A1 (en) 2009-05-13 2011-12-29 Gilead Sciences Inc Antiviral compounds
PT2595980E (pt) 2010-07-22 2014-11-27 Gilead Sciences Inc Métodos e compostos para tratar infeções pelo vírus da família paramyxoviridae
TW201306841A (zh) 2010-12-20 2013-02-16 Gilead Sciences Inc 治療c型肝炎病毒(hcv)之方法
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
US9403863B2 (en) 2011-09-12 2016-08-02 Idenix Pharmaceuticals Llc Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
HRP20180237T4 (hr) 2011-09-16 2020-12-11 Gilead Pharmasset Llc Metode za liječenje hcv-a
AR089650A1 (es) 2011-10-14 2014-09-10 Idenix Pharmaceuticals Inc Fosfatos 3,5-ciclicos sustituidos de compuestos de nucleotido de purina y composiciones farmaceuticas para el tratamiento de infecciones virales
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
DE112012003510T5 (de) 2011-10-21 2015-03-19 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如,与abt-072或abt-333)
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2852604B1 (en) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphoramidate prodrugs for hcv infection
MD20140134A2 (ro) 2012-05-22 2015-04-30 Idenix Pharmaceuticals, Inc. Compuşi ai D-aminoacizilor pentru tratamentul bolilor hepatice
WO2013177195A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphate prodrugs for hcv infection
PT2861611T (pt) 2012-05-25 2016-10-11 Janssen Sciences Ireland Uc Nucleósidos de espirooxetano de uracilo
US8927741B2 (en) 2012-08-17 2015-01-06 Gilead Sciences, Inc. Synthesis of an antiviral compound
US8759544B2 (en) * 2012-08-17 2014-06-24 Gilead Sciences, Inc. Synthesis of an antiviral compound
US8841340B2 (en) * 2012-08-17 2014-09-23 Gilead Sciences, Inc. Solid forms of an antiviral compound
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
ES2674980T3 (es) 2012-10-08 2018-07-05 Idenix Pharmaceuticals Llc Análogos de 2'-cloro nucleósidos para infección por VHC
WO2014066239A1 (en) 2012-10-22 2014-05-01 Idenix Pharmaceuticals, Inc. 2',4'-bridged nucleosides for hcv infection
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
EP2950786B1 (en) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
EP2970357B1 (en) 2013-03-13 2025-01-01 Idenix Pharmaceuticals LLC Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
EP3004130B1 (en) 2013-06-05 2019-08-07 Idenix Pharmaceuticals LLC. 1',4'-thio nucleosides for the treatment of hcv
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
JP2016527232A (ja) 2013-07-17 2016-09-08 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Hcvの治療に使用するためのビフェニル誘導体を含む組み合わせ
US20150037282A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
EA201690473A1 (ru) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Комбинированный состав двух противовирусных соединений
UA119050C2 (uk) * 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
EP3131914B1 (en) 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
CN104140417B (zh) * 2014-06-11 2016-04-06 苏州景泓生物技术有限公司 合成gs5885用的中间体的先期化合物的合成方法
SI3166607T1 (sl) 2014-07-11 2023-01-31 Gilead Sciences, Inc. Modulatorji toličnih receptorjev za zdravljenje HIV-a
TWI678369B (zh) 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並[3,2-d]嘧啶、呋喃並[3,2-d]嘧啶及吡咯並[3,2-d]嘧啶化合物類
TWI673283B (zh) 2014-08-21 2019-10-01 美商基利科學股份有限公司 2’-氯胺基嘧啶酮及嘧啶二酮核苷類
CN107074860B (zh) * 2014-09-16 2022-07-15 吉利德科学公司 制备toll样受体调节剂的方法
CN110305133A (zh) * 2014-09-16 2019-10-08 吉利德科学公司 Toll样受体调节剂的固体形式
TWI698444B (zh) 2014-10-29 2020-07-11 美商基利科學股份有限公司 製備核糖苷的方法
WO2016106050A1 (en) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
FI3265102T3 (fi) 2015-03-06 2025-10-31 Atea Pharmaceuticals Inc Beta-d-2'-deoksi-2'-alfa-fluori-2'-beta-c-substituoituja-2-modifioituja-n6-substituoituja puriininukleotideja hcv-hoitoa varten
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
DK3349758T3 (da) 2015-09-16 2022-06-13 Gilead Sciences Inc Fremgangsmåder til behandling af arenaviridae-virusinfektioner
CN105646626B (zh) * 2016-02-24 2018-04-24 贵州理工学院 一种高收率索氟布韦的合成方法
JP6551263B2 (ja) 2016-03-02 2019-07-31 株式会社デンソー ヘッドアップディスプレイ装置
CN105669358A (zh) * 2016-03-17 2016-06-15 中国药科大学 多取代芴衍生物的氟化方法
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
CN105968040B (zh) * 2016-06-29 2019-02-05 爱斯特(成都)生物制药股份有限公司 一种雷迪帕韦中间体的制备方法
CN106432197B (zh) * 2016-09-07 2019-12-10 上海众强药业有限公司 一种雷迪帕韦中间体单对甲苯磺酸盐、其晶型及其制备方法
CN115477679A (zh) 2017-02-01 2022-12-16 阿堤亚制药公司 用于治疗丙型肝炎病毒的核苷酸半硫酸盐
CN110869028B (zh) 2017-03-14 2023-01-20 吉利德科学公司 治疗猫冠状病毒感染的方法
EP4219513A1 (en) 2017-05-01 2023-08-02 Gilead Sciences, Inc. Crystalline form of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
CN111093627B (zh) 2017-07-11 2024-03-08 吉利德科学公司 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物
CA3177215C (en) 2017-09-29 2026-06-09 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate
RU2020116571A (ru) 2017-12-07 2021-11-22 Эмори Юниверсити N4-гидроксицитидин и производные и связанные с этим противовирусные применения
CA3119956A1 (en) 2018-11-14 2020-05-22 Daiichi Sankyo Company, Limited Anti-cdh6 antibody-pyrrolobenzodiazepine derivative conjugate
EP3670488A1 (en) 2018-12-18 2020-06-24 Basf Se Bi- and tricyclic ketones for use as aroma chemicals
EP3950061A4 (en) 2019-03-25 2022-11-16 Daiichi Sankyo Company, Limited ANTIBODY PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE
BR112021017616A2 (pt) 2019-03-25 2021-11-09 Daiichi Sankyo Co Ltd Conjugado de derivado de anticorpo anti-her2-pirrolobenzodiazepina
EP3949988A4 (en) 2019-03-27 2022-11-16 Daiichi Sankyo Company, Limited COMBINATION OF AN ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE AND A PARP INHIBITOR
WO2020202142A2 (en) 2019-03-31 2020-10-08 Yeda Research And Development Co. Ltd. Anti-viral and anti-tumoral compounds
CN113924114A (zh) 2019-05-22 2022-01-11 吉利德科学公司 Tlr7调节化合物和hiv疫苗的组合
KR20220132608A (ko) 2020-01-27 2022-09-30 길리애드 사이언시즈, 인코포레이티드 SARS CoV-2 감염증을 치료하기 위한 방법
CN113214262B (zh) * 2020-02-05 2023-07-07 华创合成制药股份有限公司 一种含有胍基的化合物及其制备方法和用途
KR20250133471A (ko) 2020-02-18 2025-09-05 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
TWI791193B (zh) 2020-02-18 2023-02-01 美商基利科學股份有限公司 抗病毒化合物
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
TWI785528B (zh) 2020-03-12 2022-12-01 美商基利科學股份有限公司 1’-氰基核苷之製備方法
JP7482250B2 (ja) 2020-04-06 2024-05-13 ギリアード サイエンシーズ, インコーポレイテッド 1’-シアノ置換カルバヌクレオシド類似体の吸入製剤
EP4157272B1 (en) 2020-05-29 2025-07-02 Gilead Sciences, Inc. Remdesivir for the treatment of viral infections
CN111620903A (zh) * 2020-06-17 2020-09-04 安徽贝克联合制药有限公司 C-核苷类似物以及用于合成瑞德西韦合成的含腈c-核苷类化合物的制备方法及其应用
IL299202A (en) 2020-06-24 2023-02-01 Gilead Sciences Inc 1'-cyano nucleoside analogs and uses thereof
EP4228656A4 (en) 2020-08-18 2024-09-04 Yeda Research and Development Co. Ltd ANTI-VIRAL AND ANTI-TUMOR COMPOUNDS
US11926645B2 (en) 2020-08-27 2024-03-12 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
WO2022164941A1 (en) 2021-01-26 2022-08-04 Atea Pharmaceuticals, Inc. Advantageous morphic form of at-527 hemi-sulfate salt
AU2022256476B2 (en) 2021-04-16 2025-06-05 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
AU2022279234B2 (en) 2021-05-21 2025-08-28 Gilead Sciences, Inc. Pentacyclic derivatives as zika virus inhibitors
JP7723119B2 (ja) 2021-05-21 2025-08-13 ギリアード サイエンシーズ, インコーポレイテッド ジカウイルス感染症の治療のための四環系化合物
AU2022291927A1 (en) 2021-06-17 2024-01-04 Atea Pharmaceuticals, Inc. Advantageous anti-hcv combination therapy
CA3228162A1 (en) 2021-08-18 2023-02-23 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
KR20240154647A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
EP4547665A1 (en) 2022-06-30 2025-05-07 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3798209A (en) 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
US4614719A (en) 1982-04-30 1986-09-30 Yamasa Shoyu Kabushiki Kaisha Process for producing ribavirin
RU2358979C2 (ru) * 2003-05-30 2009-06-20 Фармассет, Инк. Модифицированные фторированные аналоги нуклеозида
EP1945222B1 (en) 2005-11-02 2012-12-26 Bayer Pharma Aktiengesellschaft Pyrrolo[2,1-f] [1,2,4]-triazin-4-ylamines as igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
US7754720B2 (en) * 2006-07-07 2010-07-13 Gilead Sciences, Inc. Pyridazine compound and use thereof
US7893264B2 (en) * 2006-07-07 2011-02-22 Gilead Sciences, Inc. Antiviral phosphinate compounds
US8338593B2 (en) * 2006-07-07 2012-12-25 Gilead Sciences, Inc. Modulators of toll-like receptor 7
NZ582096A (en) * 2007-06-29 2012-05-25 Gilead Sciences Inc Antiviral compounds that inhibit hepatitis c virus (hcv)
EP2170888B1 (en) 2007-06-29 2015-04-22 Gilead Sciences, Inc. Purine derivatives and their use as modulators of toll-like receptor 7
AR068794A1 (es) 2007-06-29 2009-12-09 Gilead Sciences Inc Compuestos antivirales
UA99466C2 (en) 2007-07-06 2012-08-27 Гилиад Сайенсиз, Инк. Crystalline pyridazine compound
PL2280973T3 (pl) * 2008-04-23 2013-05-31 Gilead Sciences Inc Analogi karba-nukleozydowe do leczenia przeciwwirusowego
US7921612B2 (en) 2008-08-31 2011-04-12 United Construction Products, Inc. Method and device for supporting a structure
UY32306A (es) 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
SG176015A1 (en) * 2009-05-13 2011-12-29 Gilead Sciences Inc Antiviral compounds
DK2480552T3 (en) 2009-09-21 2017-02-20 Gilead Sciences Inc 2 'FLUOROUS-SUBSTITUTED CARBA NUCLEOSIDE ANALYSIS FOR ANTIVIRAL TREATMENT
TWI491609B (zh) 2010-01-15 2015-07-11 Gilead Sciences Inc 黃熱病毒科(Flaviviridae)病毒之抑制劑類
AP2012006535A0 (en) 2010-03-31 2012-10-31 Gilead Pharmasset Llc Stereoselective synthesis of phosphorous containing actives
TW201201815A (en) * 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
US20110306541A1 (en) 2010-06-10 2011-12-15 Gilead Sciences, Inc. Methods for treating hcv
EA025311B1 (ru) 2010-07-19 2016-12-30 Гайлид Сайэнсиз, Инк. Способы получения диастереомерно чистых фосфорамидатных пролекарств
SG188223A1 (en) 2010-09-20 2013-04-30 Gilead Sciences Inc 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
TW201306841A (zh) 2010-12-20 2013-02-16 Gilead Sciences Inc 治療c型肝炎病毒(hcv)之方法
HRP20180237T4 (hr) 2011-09-16 2020-12-11 Gilead Pharmasset Llc Metode za liječenje hcv-a

Similar Documents

Publication Publication Date Title
JP6668468B2 (ja) Hbvキャプシドアセンブリ阻害剤とインターフェロンの併用療法
JP2012502999A (ja) インターフェロンおよびリバビリンとのhcvns3プロテアーゼ阻害剤の組合せ
JP2011528713A5 (enExample)
JP2011519364A5 (enExample)
TW201532606A (zh) 使用化合物之組合治療c型肝炎病毒感染
MA33274B1 (fr) Dérivés de la thiéno [2, 3-b] pyridine servant d'inhibiteurs de réplication virale
JP2011225596A5 (enExample)
US20090304630A1 (en) Treating severe and acute viral infections
EP2585065A1 (en) Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
CN108712905B (zh) 抗肝肿瘤病毒剂
JP2011510647A5 (enExample)
JP2017514911A5 (enExample)
CN102083435A (zh) 特拉匹韦给药方案
Sullivan et al. 1210 ABT-267 COMBINED WITH PEGYLATED INTERFERON ALPHA-2A/RIBAVIRIN IN GENOTYPE 1 (GT1) HCV-INFECTED TREATMENT-NAIVE SUBJECTS: 12 WEEK ANTIVIRAL AND SAFETY ANALYSIS
Lawitz et al. 1055 antiviral activity OF ANA598, a potent NON-nucleoside polymerase inhibitor, IN chronic hepatitis C patients
WO2021129890A1 (zh) 阻断微生物感染、降低胆固醇、防治相关肿瘤的药物及其应用
CN111163792A (zh) 用于治疗病毒感染的肽
CN101076338A (zh) Aml的治疗
MX2015002684A (es) Combinacion de un inhibidor macrociclico de proteasas del vhc, un inhibidor del vhc no nucleosidico y ritonavir.
WO2008004653A1 (en) Prophylactic or therapeutic agent for viral disease
ES2968931T3 (es) Efecto sinérgico de eyp001 e ifn-alfa pegilado para el tratamiento de la infección por hbv
CN111214470A (zh) 雷帕霉素及其衍生物在制备用于预防和治疗病毒引起的ade的药品的用途
RU2013148539A (ru) Алиспоривир для лечения инфекции вируса гепатита с
CN106581052B (zh) 柠檬酸根离子和铁离子在抑制rna病毒中的应用
Ingiliz Editorial to Martinello et al.'s HCV reinfection incidence among individuals treated for recent infection